
Reading the population and comparator in a pain trial
A specialized trial does not represent every kind of pain.
Ziconotide: retain the studied setting.
A specialized trial does not represent every kind of pain.
The published question
Rauck and colleagues compared intrathecal ziconotide with placebo in a randomized trial of adults with severe chronic pain. The paper reported improved pain intensity in its primary comparison during a short study. Retain participant selection, concomitant treatments, duration and withdrawals; do not turn the finding into efficacy of “peptides” as a group.
Add the safety context
The US label contains a boxed neuropsychiatric warning and a contraindication in people with a history of psychosis. This belongs alongside a public explanation of the example. The label does not support transferring the finding to another route; it requires the complete clinical context.
Professional context / Contexto profesional
Full critical appraisal of the protocol, effect size and intervals remains pending.
Evidence / Evidencia
Randomized trial of a specific medicine and route.
Limitations / Limitaciones
No use, dosing or commercial-comparison recommendations.
References
- Rauck RL, Wallace MS, Leong MS, et al.; Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management. 2006
- DailyMed / US prescribing information submitted by Esteve Pharmaceuticals. PRIALT — ziconotide acetate injection, solution. . 2026